Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Biotech
Amgen reveals 6-point drop in lupus severity behind ph. 2 win
Amgen has shed light on its phase 2 lupus win, revealing that daxdilimab was tied to a 6-point reduction in disease severity at the lower dose.
James Waldron
Sep 30, 2026 4:26am
Amgen fusion protein eases Sjögren's severity in ph. 3 win
Sep 22, 2026 10:20am
GSK’s ADC lays down marker for lung cancer scrap with Merck
Sep 12, 2026 7:00pm
TScan’s strategy unaffected by Amgen scrapping $500M+ collab
Aug 19, 2026 5:31pm
Amgen lays groundwork for new R&D center in Hyderabad
Aug 11, 2026 2:05pm
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
Aug 4, 2026 4:01pm
